Zai Lab | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (25)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
Article By: ChinaBio® Today
Saturday, July 8, 2023 2:18 PM EDT
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic therapy developed by VBI Vaccines for $15 million.
In this article: TAK, BRIBF Also: MRNA, ARGX, VBIV, ZLAB, IVBXF
Read
Week In Review: YishengBio To List On NASDAQ Via SPAC Merger At An $834 Million Value
Article By: ChinaBio® Today
Saturday, October 1, 2022 2:40 PM EDT
Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the NASDAQ Exchange at a pre-money equity value of $834 million. The merger is expected to provide up to $230 million in cash to YishengBio.
In this article: SMIH Also: SGEN, ZLAB, 2142.HK, 3692.HK, 2096.HK, 0460.HK
Read
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
Article By: ChinaBio® Today
Saturday, July 2, 2022 1:59 PM EDT
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones.
In this article: LLY, BLRX, BGNE, ZLAB, 1801.HK, 6855.HK, 2696.HK, 9926.HK, 2142.HK, 2197.HK
Read
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
Article By: Benzinga
Sunday, January 23, 2022 2:45 PM EDT
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.
In this article: ABT, JNJ, RHHBY, UCBJY, ZGNX, VRTX, ZLAB, CUE, DCPH, ETON
Read
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
Article By: ChinaBio® Today
Saturday, December 18, 2021 3:00 PM EDT
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.
In this article: BGNE, PRTK, ABUS, ZLAB, KROS, 1801.HK, 6996.HK, 1952.HK, 3692.HK, 1530.HK
Read
All Posts

Latest Tweets for $ZLAB

No tweets yet!

PARTNER HEADLINES